Stakeholders’ feedback on the proposed recommendations for updating the Patented Medicine Prices Review Board (PMPRB) budget impact analysis guidelines
The Journal of Population Therapeutics and Clinical Pharmacology |
With the introduction of highly specialized, expensive medicines and an aging population, spending on pharmaceuticals is expected to increase significantly in Canada and other developed countries. To determine whether a drug will be approved by a drug benefit programs, a health technology assessment (HTA) and budget impact analysis (BIA) act as important components. In 2007, the first and only Canadian budget impact analysis (BIA) guidelines were published by the Patented Medicine Prices Review Board (PMPRB).
Fergal Mills, InnomarConsulting, contributes to a study obtaining feedback from Canadian stakeholders on a variety of proposed recommendations regarding updating the PMPRB’s 2007 BIA guidelines.